Briacell Income Tax Expense from 2010 to 2024

BCTX Stock  USD 0.66  0.44  40.00%   
Briacell Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense will likely drop to about 59.7 K in 2024. During the period from 2010 to 2024, Briacell Therapeutics Income Tax Expense regression line of annual values had r-squared of  0.02 and arithmetic mean of  1,326,011. View All Fundamentals
 
Income Tax Expense  
First Reported
2006-07-31
Previous Quarter
-23.2 K
Current Value
220.4 K
Quarterly Volatility
2.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 86.7 K, Interest Expense of 0.0 or Other Operating Expenses of 34.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Briacell Therapeutics Correlation against competitors.

Latest Briacell Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Briacell Therapeutics Corp over the last few years. It is Briacell Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

Briacell Income Tax Expense Regression Statistics

Arithmetic Mean1,326,011
Geometric Mean230,682
Coefficient Of Variation197.50
Mean Deviation1,782,874
Median62,852
Standard Deviation2,618,833
Sample Variance6.9T
Range8.7M
R-Value(0.12)
Mean Square Error7.3T
R-Squared0.02
Significance0.66
Slope(71,969)
Total Sum of Squares96T

Briacell Income Tax Expense History

202459.7 K
202362.9 K
2022-152.6 K
202130.7 K
20206.6 M
2019-72.3 K
2018343.7 K

About Briacell Therapeutics Financial Statements

Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense62.9 K59.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.